Market Cap 89.91M
Revenue (ttm) 0.00
Net Income (ttm) -28.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 746,900
Avg Vol 1,513,068
Day's Range N/A - N/A
Shares Out 119.35M
Stochastic %K 15%
Beta 1.09
Analysts Strong Sell
Price Target $4.87

Company Profile

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored...

Industry: Biotechnology
Sector: Healthcare
Phone: 403 670 7377
Fax: 403 283 0858
Address:
4350 Executive Drive, Suite 325, San Diego, United States
GammaRadiated
GammaRadiated Aug. 3 at 9:51 PM
$ONCY off topic has anyone received a message from Ashfotd Markets going into detail investing strategy then asking you to open an XTB account ?
0 · Reply
Rsitorv
Rsitorv Aug. 3 at 9:26 PM
$ONCY fe more interesting things. 1. There is no approved CPI in pancreatic. 2. There is only 1 approved CPI in SCAC (anal) Zynyz - owned by Incyte. 3. The colorectal trial uses no CPI and is in combo with approved therapies that are completely reimbursed and Oncy needs no drug partner for this trial. Jared completely acknowledges that past trials had questionable results. No controls. The colorectal will solve this and its the trial with biggest unmet need. No wonder ONCY doesn't want to do panc or anal without a partner. Pancreatic and anal will be the cherry on the cake for the company who partners. Will be interesting to see the pancreatic results in 4 months. Should have more FDA news the week after next.
0 · Reply
Rsitorv
Rsitorv Aug. 3 at 8:20 PM
$ONCY 2 important benchmarks are the anal cancer data 3 or 4 months and 5 or 6 months colorectal data.
1 · Reply
Rsitorv
Rsitorv Aug. 3 at 8:17 PM
$ONCY so Jared said in a recent interview that his goal coming in for partnership was 2 years. He said he has now been there a year. He expects a partnership 'within' the next year. 2 years after the year He expects multiple approvals. 3 approvals in 2-2.5 years. Needs 400 million to do it alone so they want a partner. He says the major problem of the past is that they have not run clean trials. Colorectal will change that. "We opened up a number of sites, patients are beginning to, um, be right on the cusp of enrollment just waiting out certain periods , and then by the end of year or early January we will have new controlled clinical data in the colorectal study"....in a controlled study.
0 · Reply
GoPatzGo123
GoPatzGo123 Aug. 3 at 4:24 PM
$ONCY fuck it bought another 5k only money
0 · Reply
CaseyLe
CaseyLe Aug. 3 at 4:12 PM
$ONCY i’ll buy more next week hopefully it’ll still be in the 70s 
0 · Reply
GammaRadiated
GammaRadiated Aug. 3 at 3:46 PM
$ONCY Added another 10,000 shares-
1 · Reply
FoxM07
FoxM07 Aug. 2 at 10:29 PM
0 · Reply
Notable_Ex
Notable_Ex Aug. 2 at 8:34 PM
$ONCY Neither is Replimmune a Canadian company on Stockhouse.
0 · Reply
FoxM07
FoxM07 Aug. 2 at 8:14 PM
$ONCY report not-able-x & their conjecture & spam.
0 · Reply
Latest News on ONCY
Oncolytics provides clinical, regulatory update on REO 033

2026-07-13T13:10:54.000Z - 21 days ago

Oncolytics provides clinical, regulatory update on REO 033


Oncolytics secures new patent for pelareorep manufacturing

2026-06-16T13:38:20.000Z - 6 weeks ago

Oncolytics secures new patent for pelareorep manufacturing


Oncolytics promotes John McAdory to COO

2026-06-02T14:21:34.000Z - 2 months ago

Oncolytics promotes John McAdory to COO

CGON


Oncolytics Biotech Slides: Investor presentation

Jun 1, 2026, 7:00 AM EDT - 2 months ago

Oncolytics Biotech Slides: Investor presentation


Oncolytics Biotech to present data at ASCO 2026 on pelareorep

2026-05-22T13:45:50.000Z - 2 months ago

Oncolytics Biotech to present data at ASCO 2026 on pelareorep


Oncolytics Biotech Quarterly report: Q1 2026

May 14, 2026, 4:00 PM EDT - 2 months ago

Oncolytics Biotech Quarterly report: Q1 2026


Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study

Apr 27, 2026, 8:10 AM EDT - 3 months ago

Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study


Oncolytics Biotech Slides: Investor presentation

Apr 27, 2026, 7:00 AM EDT - 3 months ago

Oncolytics Biotech Slides: Investor presentation


Oncolytics price target lowered to $5 from $7 at Lake Street

2026-04-07T14:24:37.000Z - 4 months ago

Oncolytics price target lowered to $5 from $7 at Lake Street


Oncolytics completes domicile change to the U.S.

2026-04-01T13:39:37.000Z - 4 months ago

Oncolytics completes domicile change to the U.S.


Oncolytics Biotech Registration statement: Registration filing

Apr 1, 2026, 8:00 AM EDT - 4 months ago

Oncolytics Biotech Registration statement: Registration filing


Oncolytics files $250M mixed securities shelf

2026-04-01T10:11:38.000Z - 4 months ago

Oncolytics files $250M mixed securities shelf


Oncolytics Biotech Annual report: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 4 months ago

Oncolytics Biotech Annual report: Q4 2025


Oncolytics to present new data on Pelareorep at AACR 2026

2026-03-19T13:16:47.000Z - 4 months ago

Oncolytics to present new data on Pelareorep at AACR 2026


Oncolytics Biotech Slides: Corporate presentation

Mar 3, 2026, 6:00 AM EST - 5 months ago

Oncolytics Biotech Slides: Corporate presentation


Oncolytics initiates randomized colorectal cancer study

2026-03-02T14:12:44.000Z - 5 months ago

Oncolytics initiates randomized colorectal cancer study


Oncolytics concludes enrollment in GOBLET study

2026-02-24T14:05:55.000Z - 5 months ago

Oncolytics concludes enrollment in GOBLET study


Oncolytics receives FDA Fast Track Designation for pelareorep

2026-02-04T13:55:27.000Z - 6 months ago

Oncolytics receives FDA Fast Track Designation for pelareorep


Oncolytics Biotech Transcript: AGM 2026

Jan 15, 2026, 10:00 AM EST - 7 months ago

Oncolytics Biotech Transcript: AGM 2026


Oncolytics Biotech Slides: Investor presentation

Jan 14, 2026, 7:00 AM EST - 7 months ago

Oncolytics Biotech Slides: Investor presentation


Oncolytics announces updates data from GOBLET cohort 4

2026-01-12T14:10:53.000Z - 7 months ago

Oncolytics announces updates data from GOBLET cohort 4


Oncolytics Biotech Earnings release: Q3 2025

Nov 11, 2025, 6:00 PM EST - 9 months ago

Oncolytics Biotech Earnings release: Q3 2025


Oncolytics Biotech Transcript: AGM 2025

Aug 8, 2025, 10:00 AM EDT - 1 year ago

Oncolytics Biotech Transcript: AGM 2025


Oncolytics Biotech Earnings release: Q2 2025

Aug 8, 2025, 10:00 AM EDT - 1 year ago

Oncolytics Biotech Earnings release: Q2 2025


Oncolytics Biotech Transcript: Status Update

Jul 22, 2025, 1:00 PM EDT - 1 year ago

Oncolytics Biotech Transcript: Status Update


Oncolytics Biotech Earnings Call Transcript: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Oncolytics Biotech Earnings Call Transcript: Q1 2025


Oncolytics Biotech Earnings release: Q1 2025

May 14, 2025, 4:30 PM EDT - 1 year ago

Oncolytics Biotech Earnings release: Q1 2025


Oncolytics Biotech Earnings Call Transcript: Q4 2024

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oncolytics Biotech Earnings Call Transcript: Q4 2024


Oncolytics Biotech Annual report: Q4 2024

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oncolytics Biotech Annual report: Q4 2024


Oncolytics Biotech Earnings release: Q4 2024

Mar 7, 2025, 8:30 AM EST - 1 year ago

Oncolytics Biotech Earnings release: Q4 2024


GammaRadiated
GammaRadiated Aug. 3 at 9:51 PM
$ONCY off topic has anyone received a message from Ashfotd Markets going into detail investing strategy then asking you to open an XTB account ?
0 · Reply
Rsitorv
Rsitorv Aug. 3 at 9:26 PM
$ONCY fe more interesting things. 1. There is no approved CPI in pancreatic. 2. There is only 1 approved CPI in SCAC (anal) Zynyz - owned by Incyte. 3. The colorectal trial uses no CPI and is in combo with approved therapies that are completely reimbursed and Oncy needs no drug partner for this trial. Jared completely acknowledges that past trials had questionable results. No controls. The colorectal will solve this and its the trial with biggest unmet need. No wonder ONCY doesn't want to do panc or anal without a partner. Pancreatic and anal will be the cherry on the cake for the company who partners. Will be interesting to see the pancreatic results in 4 months. Should have more FDA news the week after next.
0 · Reply
Rsitorv
Rsitorv Aug. 3 at 8:20 PM
$ONCY 2 important benchmarks are the anal cancer data 3 or 4 months and 5 or 6 months colorectal data.
1 · Reply
Rsitorv
Rsitorv Aug. 3 at 8:17 PM
$ONCY so Jared said in a recent interview that his goal coming in for partnership was 2 years. He said he has now been there a year. He expects a partnership 'within' the next year. 2 years after the year He expects multiple approvals. 3 approvals in 2-2.5 years. Needs 400 million to do it alone so they want a partner. He says the major problem of the past is that they have not run clean trials. Colorectal will change that. "We opened up a number of sites, patients are beginning to, um, be right on the cusp of enrollment just waiting out certain periods , and then by the end of year or early January we will have new controlled clinical data in the colorectal study"....in a controlled study.
0 · Reply
GoPatzGo123
GoPatzGo123 Aug. 3 at 4:24 PM
$ONCY fuck it bought another 5k only money
0 · Reply
CaseyLe
CaseyLe Aug. 3 at 4:12 PM
$ONCY i’ll buy more next week hopefully it’ll still be in the 70s 
0 · Reply
GammaRadiated
GammaRadiated Aug. 3 at 3:46 PM
$ONCY Added another 10,000 shares-
1 · Reply
FoxM07
FoxM07 Aug. 2 at 10:29 PM
0 · Reply
Notable_Ex
Notable_Ex Aug. 2 at 8:34 PM
$ONCY Neither is Replimmune a Canadian company on Stockhouse.
0 · Reply
FoxM07
FoxM07 Aug. 2 at 8:14 PM
$ONCY report not-able-x & their conjecture & spam.
0 · Reply
Notable_Ex
Notable_Ex Aug. 2 at 8:13 PM
0 · Reply
FoxM07
FoxM07 Aug. 2 at 8:13 PM
0 · Reply
FoxM07
FoxM07 Aug. 2 at 8:12 PM
0 · Reply
FoxM07
FoxM07 Aug. 2 at 8:12 PM
0 · Reply
Notable_Ex
Notable_Ex Aug. 2 at 8:11 PM
0 · Reply
FoxM07
FoxM07 Aug. 2 at 8:11 PM
0 · Reply
Notable_Ex
Notable_Ex Aug. 2 at 8:11 PM
$ONCY The possibility of AstraZeneca using the deal to redomicile in the US is being raised.
0 · Reply
FoxM07
FoxM07 Aug. 2 at 8:11 PM
0 · Reply
Notable_Ex
Notable_Ex Aug. 2 at 8:03 PM
$ONCY The macro biopharma M&A supercycle sparked by the AstraZeneca-BMS talks is a major positive catalyst for late-stage oncology companies like ONCY. As corporate giants consolidate to absorb multi-billion dollar patent cliffs, they will aggressively target de-risked, clinical-stage oncology platforms to replenish their pipelines.
0 · Reply
Notable_Ex
Notable_Ex Aug. 2 at 7:58 PM
$ONCY This $400 billion megadeal signals that Big Pharma is shifting from defensive, bolt-on acquisitions to aggressive, scale-driven consolidation. It officially marks the end of the post-pandemic lull and validates a new, high-stakes Mergers and Acquisitions (M&A) supercycle.
0 · Reply
Notable_Ex
Notable_Ex Aug. 2 at 7:47 PM
$ONCY M& A heating up .
0 · Reply
FoxM07
FoxM07 Aug. 2 at 7:41 PM
0 · Reply